Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs: citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and clopidogrel, an antiplatelet agent. Citalopram increases serotonin levels in the brain by inhibiting its reuptake into presynaptic cells, primarily used for treating depression and anxiety disorders. Clopidogrel is a P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits platelet aggregation to reduce the risk of cardiovascular events such as heart attack and stroke. The combination may be prescribed in patients with coexisting depression and cardiovascular disease but requires careful monitoring due to increased bleeding risk[2][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + clopidogrel.